Cargando…

Peripheral Markers of Depression

Major Depressive Disorder (MDD) is a leading cause of disability worldwide, creating a high medical and socioeconomic burden. There is a growing interest in the biological underpinnings of depression, which are reflected by altered levels of biological markers. Among others, enhanced inflammation ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Nobis, Aleksander, Zalewski, Daniel, Waszkiewicz, Napoleon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760788/
https://www.ncbi.nlm.nih.gov/pubmed/33255237
http://dx.doi.org/10.3390/jcm9123793
_version_ 1783627415733403648
author Nobis, Aleksander
Zalewski, Daniel
Waszkiewicz, Napoleon
author_facet Nobis, Aleksander
Zalewski, Daniel
Waszkiewicz, Napoleon
author_sort Nobis, Aleksander
collection PubMed
description Major Depressive Disorder (MDD) is a leading cause of disability worldwide, creating a high medical and socioeconomic burden. There is a growing interest in the biological underpinnings of depression, which are reflected by altered levels of biological markers. Among others, enhanced inflammation has been reported in MDD, as reflected by increased concentrations of inflammatory markers—C-reactive protein, interleukin-6, tumor necrosis factor-α and soluble interleukin-2 receptor. Oxidative and nitrosative stress also plays a role in the pathophysiology of MDD. Notably, increased levels of lipid peroxidation markers are characteristic of MDD. Dysregulation of the stress axis, along with increased cortisol levels, have also been reported in MDD. Alterations in growth factors, with a significant decrease in brain-derived neurotrophic factor and an increase in fibroblast growth factor-2 and insulin-like growth factor-1 concentrations have also been found in MDD. Finally, kynurenine metabolites, increased glutamate and decreased total cholesterol also hold promise as reliable biomarkers for MDD. Research in the field of MDD biomarkers is hindered by insufficient understanding of MDD etiopathogenesis, substantial heterogeneity of the disorder, common co-morbidities and low specificity of biomarkers. The construction of biomarker panels and their evaluation with use of new technologies may have the potential to overcome the above mentioned obstacles.
format Online
Article
Text
id pubmed-7760788
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77607882020-12-26 Peripheral Markers of Depression Nobis, Aleksander Zalewski, Daniel Waszkiewicz, Napoleon J Clin Med Review Major Depressive Disorder (MDD) is a leading cause of disability worldwide, creating a high medical and socioeconomic burden. There is a growing interest in the biological underpinnings of depression, which are reflected by altered levels of biological markers. Among others, enhanced inflammation has been reported in MDD, as reflected by increased concentrations of inflammatory markers—C-reactive protein, interleukin-6, tumor necrosis factor-α and soluble interleukin-2 receptor. Oxidative and nitrosative stress also plays a role in the pathophysiology of MDD. Notably, increased levels of lipid peroxidation markers are characteristic of MDD. Dysregulation of the stress axis, along with increased cortisol levels, have also been reported in MDD. Alterations in growth factors, with a significant decrease in brain-derived neurotrophic factor and an increase in fibroblast growth factor-2 and insulin-like growth factor-1 concentrations have also been found in MDD. Finally, kynurenine metabolites, increased glutamate and decreased total cholesterol also hold promise as reliable biomarkers for MDD. Research in the field of MDD biomarkers is hindered by insufficient understanding of MDD etiopathogenesis, substantial heterogeneity of the disorder, common co-morbidities and low specificity of biomarkers. The construction of biomarker panels and their evaluation with use of new technologies may have the potential to overcome the above mentioned obstacles. MDPI 2020-11-24 /pmc/articles/PMC7760788/ /pubmed/33255237 http://dx.doi.org/10.3390/jcm9123793 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Nobis, Aleksander
Zalewski, Daniel
Waszkiewicz, Napoleon
Peripheral Markers of Depression
title Peripheral Markers of Depression
title_full Peripheral Markers of Depression
title_fullStr Peripheral Markers of Depression
title_full_unstemmed Peripheral Markers of Depression
title_short Peripheral Markers of Depression
title_sort peripheral markers of depression
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760788/
https://www.ncbi.nlm.nih.gov/pubmed/33255237
http://dx.doi.org/10.3390/jcm9123793
work_keys_str_mv AT nobisaleksander peripheralmarkersofdepression
AT zalewskidaniel peripheralmarkersofdepression
AT waszkiewicznapoleon peripheralmarkersofdepression